New combo shows promise for tough liver and bile duct cancers

NCT ID NCT03092895

Completed Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new combination treatment for people with advanced liver cancer or bile duct cancer. The treatment combines an immunotherapy drug (SHR-1210) with either a targeted therapy (apatinib) or chemotherapy. The goal was to see if the combination is safe and can shrink tumors. The study included 157 adults who had either failed prior treatment or were starting treatment for the first time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer liver cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BILIARY TRACT CARCINOMA ADVANCED PRIMARY LIVER CANCER

Contacts and locations

Locations

81 Hospital Nanjing

Nanjing, Jiangsu, 210002, China
Cancer Hospital of Henan province

Zhengzhou, Henan, 450008, China
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China
Hunan Cancer Hospital

Hunan, Changsha, 410000, China
The First Affiliated Hospital of Nanchang University

Jiangxi, Nanchang, 330006, China
The Second Affiliated Hospital Of Anhui Medical University

Hefei, Anhui, 230000, China
Zhongshan Hospital

Shanghai, Shanghai Municipality, 200003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.